Last reviewed · How we verify

Krintafel — Competitive Intelligence Brief

Krintafel (TAFENOQUINE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: tafenoquine. Area: Rare Disease.

marketed tafenoquine Rare Disease Small molecule Live · refreshed every 30 min

Target snapshot

Krintafel (TAFENOQUINE) — 60 Degrees Pharms. Tafenoquine works by targeting the parasite's heme detoxification pathway, preventing the parasite from producing heme and ultimately leading to its death.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Krintafel TARGET TAFENOQUINE 60 Degrees Pharms marketed tafenoquine 2018-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (tafenoquine class)

  1. 60 Degrees Pharms · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Krintafel — Competitive Intelligence Brief. https://druglandscape.com/ci/tafenoquine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: